A Randomized-Withdrawal, Double-Masked, Placebo-Controlled Study of the Efficacy and Safety of Gevokizumab in Treating Subjects With Behcet's Disease Uveitis

Trial Profile

A Randomized-Withdrawal, Double-Masked, Placebo-Controlled Study of the Efficacy and Safety of Gevokizumab in Treating Subjects With Behcet's Disease Uveitis

Discontinued
Phase of Trial: Phase III

Latest Information Update: 24 Oct 2015

At a glance

  • Drugs Gevokizumab (Primary)
  • Indications Behcet's syndrome; Uveitis
  • Focus Registrational; Therapeutic Use
  • Acronyms EYEGUARD™-US
  • Sponsors XOMA
  • Most Recent Events

    • 15 Oct 2015 Planned primary completion date changed from 1 Sep 2015 to 1 Oct 2015 as per ClinicalTrials.gov.record.
    • 15 Oct 2015 Status changed from recruiting to discontinued as per ClinicalTrials.gov.record.
    • 04 Nov 2014 Status changed from not yet recruiting to recruiting as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top